Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 2, 2010, Pages 143-155

  Köhler, Ralf ^a   Kaistha, Brajesh P ^a,b   Wulff, Heike ^a,c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antihypertensives; Ca2+ activated K+ channels; EDHF; Hypertension; KCa2.3; KCa3.1; Restenosis

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 1 (3,5 BIS TRIFLUOROMETHYLPHENYL) 3 [4 BROMO 2 (1H TETRAZOL 5 YL)PHENYL]THIOUREA; 1 ETHYL 2 BENZIMIDAZOLINONE; 1,3 DIHYDRO 1 [2 HYDROXY 5 (TRIFLUOROMETHYL)PHENYL] 5 (TRIFLUOROMETHYL) 2H BENZIMIDAZOL 2 ONE; 2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 3 OXIME 6,7 DICHLORO 1H INDOLE 2,3 DIONE; 5,6 DICHLORO 1 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOLE 2 ONE; [N (3 TRIFLUOROMETHYL)PHENYL] N' (2 HYDROXY 5 CHLOROPHENYL)UREA; ANTIHYPERTENSIVE AGENT; BENZOTHIAZEPINE DERIVATIVE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CARDIOVASCULAR AGENT; CYCLOHEXYL[2 (3,5 DIMETHYLPYRAZOL 1 YL) 6 METHYLPYRIMIDIN 4 YL]AMINE; DEHYDROSOYASAPONIN 1; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ESTROGEN DERIVATIVE; GSK 1016790 A; NAPHTHO[1,2 D]THIAZOL 2 AMINE; NIFEDIPINE; NS 11021; NS 1608; NS 309; OMEGA 3 FATTY ACID; PHOSPHODIESTERASE III INHIBITOR; POLYPHENOL DERIVATIVE; POTASSIUM CHANNEL STIMULATING AGENT; SENICAPOC; SKA 31; TRAM 34; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; BIOLOGICAL FACTOR; ENDOTHELIUM DEPENDENT HYPERPOLARIZATION FACTOR; ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION FACTOR; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNMA1 PROTEIN, HUMAN; KCNN4 PROTEIN, HUMAN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNIT;

ARTERY DILATATION; ARTERY INTIMA PROLIFERATION; ARTERY TONE; ASTHMA; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BRADYCARDIA; CALCIUM SIGNALING; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHANNEL GATING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; EDEMA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FIBROSIS; LOCOMOTION; MEMBRANE DEPOLARIZATION; MUSCLE CONTRACTION; NAUSEA; NONHUMAN; PHYSICAL ACTIVITY; PROTEIN TARGETING; RESTENOSIS; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; STROKE; VASCULAR SMOOTH MUSCLE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNITS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; VASCULAR DISEASES; VASODILATION;

EID: 74949130493     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903540257     Document Type: Review

References (95)

1. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004;15:1983-1992
2. Spieker LE, Flammer AJ, Luscher TF. The vascular endothelium in hypertension. Handb Exp Pharmacol 2006:249-283
3. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006;291:H985-1002
4. Zargham R. Preventing restenosis after angioplasty: a multistage approach. Clin Sci (Lond) 2008;114:257-264
5. Grgic I, Kaistha BP, Hoyer J, et al. Endothelial Ca2+-activated K+ channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 2009;157:509-526
6. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376
7. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526 (Pubitemid 17085822)
8. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-665
9. De Mey JG, Claeys M, Vanhoutte PM. Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery. J Pharmacol Exp Ther 1982;222:166-173
10. Busse R, Edwards G, Feletou M, et al. EDHF: bringing the concepts together. Trends Pharmacol Sci 2002;23:374-380
11. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 2006;26:1215-1225
12. Köhler R, Hoyer J. The endothelium-derived hyperpolarizing factor: insights from genetic animal models. Kidney Int 2007;72:145-150
13. Shimokawa H, Yasutake H, Fujii K, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 1996;28:703-711
14. Brahler S, Kaistha A, Schmidt VJ, et al. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 2009;119:2323-2332
15. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 2007;49:590-596
16. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-497 (Pubitemid 29470209)
17. Faraci FM, Sobey CG, Chrissobolis S, et al. Arachidonate dilates basilar artery by lipoxygenase-dependent mechanism and activation of K+ channels. Am J Physiol Regul Integr Comp Physiol 2001;281:R246-53
18. Bolotina VM, Najibi S, Palacino JJ, et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994;368:850-853
19. Shimokawa H, Morikawa K. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans. J Mol Cell Cardiol 2005;39:725-732
20. Griffith TM. Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis? Br J Pharmacol 2004;141:881-903
21. Edwards G, Dora KA, Gardener MJ, et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998;396:269-272 (Pubitemid 28541391)
22. Wei AD, Gutman GA, Aldrich R, et al. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 2005;57:463-472
23. Ishii TM, Silvia C, Hirschberg B, et al. A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci USA 1997;94:11651-11656
24. Köhler M, Hirschberg B, Bond CT, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science 1996;273:1709-1714
25. Fanger CM, Ghanshani S, Logsdon NJ, et al. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J Biol Chem 1999;274:5746-5754
26. Feletou M. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options? Br J Pharmacol 2009;156:545-562
27. Nilius B, Droogmans G. Ion channels and their functional role in vascular endothelium. Physiol Rev 2001;81:1415-1459
28. Si H, Heyken WT, Wölfle SE, et al. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res 2006;99:537-544
29. Taylor MS, Bonev AD, Gross TP, et al. Altered expression of small-conductance Ca2+-activated K+ (SK3) channels modulates arterial tone and blood pressure. Circ Res 2003;93:124-131
30. Weston AH, Absi M, Ward DT, et al. Evidence in favor of a calcium-sensing receptor in arterial endothelial cells: studies with calindol and Calhex 231. Circ Res 2005;97:391-398
31. Saliez J, Bouzin C, Rath G, et al. Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation: Ca2+ signals and gap junction function are regulated by caveolin in endothelial cells. Circulation 2008;117:1065-1074
32. Dora KA, Gallagher NT, McNeish A, et al. Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res 2008;102:1247-1255
33. Ledoux J, Taylor MS, Bonev AD, et al. Functional architecture of inositol 1,4,5-trisphosphate signaling in restricted spaces of myoendothelial projections. Proc Natl Acad Sci USA 2008;105:9627-9632
34. Sinal CJ, Miyata M, Tohkin M, et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000;275:40504-40510
35. Yildiz O. Vascular smooth muscle and endothelial functions in aging. Ann NY Acad Sci 2007;1100:353-360
36. Feletou M, Vanhoutte PM. EDHF: new therapeutic targets? Pharmacol Res 2004;49:565-580
37. Köhler R, Eichler I, Schonfelder H, et al. Impaired EDHF-mediated vasodilation and function of endothelial Ca-activated K channels in uremic rats. Kidney Int 2005;67:2280-2287
38. Köhler R, Brakemeier S, Kuhn M, et al. Impaired hyperpolarization in regenerated endothelium after balloon catheter injury. Circ Res 2001;89:174-179
39. Burnham MP, Johnson IT, Weston AH. Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in Type II diabetic ZDF rats. Br J Pharmacol 2006;148:434-441
40. Weston AH, Absi M, Harno E, et al. The expression and function of Ca2+-sensing receptors in rat mesenteric artery; comparative studies using a model of type II diabetes. Br J Pharmacol 2008;154:652-662
41. Feng J, Liu Y, Clements RT, et al. Calcium-activated potassium channels contribute to human coronary microvascular dysfunction after cardioplegic arrest. Circulation 2008;118:S46-51
42. Liu Y, Sellke EW, Feng J, et al. Calcium-activated potassium channels contribute to human skeletal muscle microvascular endothelial dysfunction related to cardiopulmonary bypass. Surgery 2008;144:239-244
43. Li J, Zhou Z, Jiang DJ, et al. Reduction of NO- and EDHF-mediated vasodilatation in hypertension: role of asymmetric dimethylarginine. Clin Exp Hypertens 2007;29:489-501
44. Urakami-Harasawa L, Shimokawa H, Nakashima M, et al. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest 1997;100:2793-2799
45. Brenner R, Perez GJ, Bonev AD, et al. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. Nature 2000;407:870-876
46. Plüger S, Faulhaber J, Furstenau M, et al. Mice with disrupted BK channel beta1 subunit gene feature abnormal Ca2+ spark/STOC coupling and elevated blood pressure. Circ Res 2000;87:E53-60
47. Sausbier M, Arntz C, Bucurenciu I, et al. Elevated blood pressure linked to primary hyperaldosteronism and impaired vasodilation in BK channel-deficient mice. Circulation 2005;112:60-68
48. Grimm PR, Irsik DL, Settles DC, et al. Hypertension of Kcnmb1-/- is linked to deficient K secretion and aldosteronism. Proc Natl Acad Sci USA 2009;106:11800-11805
49. Werner ME, Zvara P, Meredith AL, et al. Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel. J Physiol 2005;567:545-556
50. Werner ME, Meredith AL, Aldrich RW, et al. Hypercontractility and impaired sildenafil relaxations in the BKCa channel deletion model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol 2008;295:R181-8
51. Amberg GC, Santana LF. Downregulation of the BK channel beta1 subunit in genetic hypertension. Circ Res 2003;93:965-971
52. Amberg GC, Bonev AD, Rossow CF, et al. Modulation of the molecular composition of large conductance, Ca2+ activated K+ channels in vascular smooth muscle during hypertension. J Clin Invest 2003;112:717-724
53. Bonnet S, Savineau JP, Barillot W, et al. Role of Ca2+-sensitive K+ channels in the remission phase of pulmonary hypertension in chronic obstructive pulmonary diseases. Cardiovasc Res 2003;60:326-336
54. Bratz IN, Dick GM, Partridge LD, et al. Reduced molecular expression of K+ channel proteins in vascular smooth muscle from rats made hypertensive with Nw-nitro-L-arginine. Am J Physiol Heart Circ Physiol 2005;289:H1277-83
55. Nishimaru K, Eghbali M, Lu R, et al. Functional and molecular evidence of MaxiK channel beta1 subunit decrease with coronary artery ageing in the rat. J Physiol 2004a;559:849-862
56. Senti M, Fernandez-Fernandez JM, Tomas M, et al. Protective effect of the KCNMB1 E65K genetic polymorphism against diastolic hypertension in aging women and its relevance to cardiovascular risk. Circ Res 2005;97:1360-1365
57. Fernandez-Fernandez JM, Tomas M, Vazquez E, et al. Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension. J Clin Invest 2004;113:1032-1039
58. Wulff H, Zhorov BS. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 2008;108:1744-1773
59. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, et al. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem 2007;14:1437-1457
60. Devor DC, Singh AK, Frizzell RA, et al. Modulation of Cl- secretion by benzimidazolones. I. Direct activation of a Ca(2+)-dependent K+ channel. Am J Physiol 1996;271:L775-84
61. Singh S, Syme CA, Singh AK, et al. Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2001;296:600-611
62. Strobaek D, Teuber L, Jorgensen TD, et al. Activation of human IK and SK Ca2+ -activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Biochim Biophys Acta 2004;1665:1-5
63. Morimura K, Yamamura H, Ohya S, et al. Voltage-dependent Ca2+-channel block by openers of intermediate and small conductance Ca2+-activated K+ channels in urinary bladder smooth muscle cells. J Pharmacol Sci 2006;100:237-241
64. Grunnet M, Jespersen T, Angelo K, et al. Pharmacological modulation of SK3 channels. Neuropharmacology 2001;40:879-887
65. Sankaranarayanan A, Raman G, Busch C, et al. Naphtho[1,2-d]thiazol-2- ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 2009;75:281-295
66. Hougaard C, Eriksen BL, Jørgensen S, et al. Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol 2007 51:655-665
67. Strobaek D, Christophersen P, Holm NR, et al. Modulation of the Ca2+-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+. Neuropharmacology 1996;35:903-914
68. Cai S, Garneau L, Sauve R. Single-channel characterization of the pharmacological properties of the K(Ca2+) channel of intermediate conductance in bovine aortic endothelial cells. J Membr Biol 1998;163:147-158
69. Bentzen BH, Nardi A, Calloe K, et al. The small molecule NS11021 is a potent and specific activator of Ca2+-activated big-conductance K+ channels. Mol Pharmacol 2007;72:1033-1044
70. Gribkoff VK, Starrett JE Jr, Dworetzky SI, et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 2001;7:471-477
71. McManus OB, Harris GH, Giangiacomo KM, et al. An activator of calcium-dependent potassium channels isolated from a medicinal herb. Biochemistry 1993;32:6128-6133
72. Leuranguer V, Gluais P, Vanhoutte PM, et al. Openers of calcium-activated potassium channels and endothelium-dependent hyperpolarizations in the guinea pig carotid artery. Naunyn Schmiedebergs Arch Pharmacol 2008;377:101-109
73. Feletou M. K+ channels and endothelial dysfunction - therapeutic option? [abstract S4.4]. Fundam Clin Pharmacol 2008;22(Suppl 2):9
74. Dalsgaard T, Kroigaard C, Bek T, et al. Role of calcium-activated potassium channels with small conductance in bradykinin-induced vasodilation of porcine retinal arterioles. Invest Ophthalmol Vis Sci 2009;50(8):3819-3825
75. Stankevicius E, Hiughes AD, Simonsen U. K+ channels and release of nitric oxide [abstract S4.3]. Fundam Clin Pharmacol 2008;22(Suppl 2):9
76. Starrett JE, Hewawasam P, Ortiz AA, et al. Synthesis, pharmacokinetic analysis and MCAO stroke activity of the maxi-K opener BMS-204352. Proceedings of the Keystone symposium: potassium channels: structure, function and therapeutic utilities Keystone, Colorado; 2000. p. 57
77. Jensen BS. BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev 2002;8:353-360
78. Nardi A, Olesen SP. BK channel modulators: a comprehensive overview. Curr Med Chem 2008;15:1126-1146
79. Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006;17:1165-1176
80. Zhao G, Zhao Y, Pan B, et al. Hypersensitivity of BKCa to Ca2+ sparks underlies hyporeactivity of arterial smooth muscle in shock. Circ Res 2007;101:493-502
81. Pedarzani P, Stocker M. Molecular and cellular basis of small- and intermediate-conductance, calcium-activated potassium channel function in the brain. Cell Mol Life Sci 2008;65:3196-3217
82. Neylon CB, Lang RJ, Fu Y, et al. Molecular cloning and characterization of the intermediate-conductance Ca2+-activated K+ channel in vascular smooth muscle: relationship between KCa channel diversity and smooth muscle cell function. Circ Res 1999;85:e33-43
83. Köhler R, Wulff H, Eichler I, et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 2003;108:1119-1125
84. Tharp DL, Wamhoff BR, Wulff H, et al. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 2008;28:1084-1089
85. Si H, Grgic I, Heyken WT, et al. Mitogenic modulation of Ca2+-activated K+ channels in proliferating A7r5 vascular smooth muscle cells. Br J Pharmacol 2006;148:909-917
86. Cheong A, Bingham AJ, Li J, et al. Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell 2005;20:45-52
87. Toyama K, Wulff H, Chandy KG, et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 2008;118:3025-3037
88. Grgic I, Kiss E, Kaistha BP, et al. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci USA 2009;106:14518-14523
89. Grgic I, Wulff H, Eichler I, et al. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc 2009;41:2601-2606
90. Köhler R, Degenhardt C, Kuhn M, et al. Expression and function of endothelial Ca2+-activated K+ channels in human mesenteric artery: a single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in situ. Circ Res 2000;87:496-503
91. Grgic I, Eichler I, Heinau P, et al. Selective blockade of the intermediate-conductance Ca2+-activated K+ channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 2005;25:704-709
92. McNaughton-Smith GA, Burns JF, Stocker JW, et al. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem 2008;51:976-982
93. Ataga KI, Orringer EP, Styles L, et al. Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy 2006;26:557-564
94. Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008;111:3991-3997
95. Willette RN, Bao W, Nerurkar S, et al. Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: part 2. J Pharmacol Exp Ther 2008;326:443-452